Abstract
Therapeutically targeting CD138, a define multiple myeloma (MM) antigen, is not yet approved for patients. We here developed and determined the preclinical efficacy of VIS832, a novel therapeutic monoclonal antibody (MoAb) with differentiated CD138 target binding to BB4 that is anti-CD138 MoAb scaffold for indatuximab ravtansine (BT062). VIS832 demonstrated enhanced CD138-binding avidity and significantly improved potency to kill MM cell lines and autologous patient MM cells regardless of resistance to current standard-of-care therapies, via robust antibody-dependent cellular cytotoxicity and phagocytosis mediated by NK and macrophage effector cells, respectively. Specifically, CD38-targeting daratumumab-resistant MM cells were highly susceptible to VIS832 which, unlike daratumumab, spares NK cells. Superior maximal cytolysis of VIS832 vs. daratumumab corresponded to higher CD138 vs. CD38 levels in MM cells. Furthermore, VIS832 acted synergistically with lenalidomide or bortezomib to deplete MM cells. Importantly, VIS832 at a sub-optimal dose inhibited disseminated MM1S tumors in vivo as monotherapy (Pā<ā0.0001), and rapidly eradicated myeloma burden in all mice concomitantly receiving bortezomib, with 100% host survival. Taken together, these data strongly support clinical development of VIS832, alone and in combination, for the therapeutic treatment of MM in relapsed and refractory patients while pointing to its potential therapeutic use earlier in disease intervention.
Similar content being viewed by others
Introduction
Multiple myeloma (MM) is characterized by excess monoclonal plasma cells (PCs) in the bone marrow (BM) producing monoclonal immunoglobulins, and is associated with hypercalcemia, renal dysfunction, anemia, and osteolytic bone disease1,2. Despite the recent use of novel therapies including proteasome inhibitors, i.e., bortezomib (btz), immunomodulatory drugs (IMiDs), i.e., lenalidomide (len) and pomalidomide (pom), and monoclonal antibodies (mAbs), i.e., daratumumab (dara) and isatuximab targeting CD38, alone or in combination, MM remains an incurable disease in most patients due to the development of drug resistance underlying relapse of disease3,4. Thus, it is urgent to develop well tolerated novel targeted immunotherapies to treat relapsed and refractory (RR) MM, which can then be used to treat earlier stages of disease and further improve patient outcome.
CD138 (Syndecan-1, SDC1), a member of the integral membrane family of heparan sulfate proteoglycans, is highly expressed on differentiated PCs. It is overexpressed in patient MM cells compared with normal PCs, and a validated diagnostic biomarker of MM. Importantly, CD138 is a co-receptor for MM cell growth, adhesion, and survival5,6,7,8, as well as other critical aspects of myeloma biology9,10,11,12,13. Its expression further correlates with disease progression and prognosis14,15,16. Thus, CD138 is a promising antigen for mAb-based immunotherapy of all stages of MM. Although CD138 targeted agents have and will be developed first to treat RRMM, CD138 is also expressed on smoldering myeloma (SMM), prior to the development of MM without evidence of end-organ damage17,18,19. Indeed, several clinical trials of MM therapies are now under evaluation to delay the progression of SMM to active disease20,21,22,23,24. Such therapies must not only delay progression of disease, but also be well tolerated, since these patients are asymptomatic.
To date, targeting CD138 for treatment of MM was clinically evaluated using indatuximab ravtansine (BT062), an anti-CD138 mAb (BB4) drug conjugate (ADC) specifically delivering a cytotoxic maytansine derivative to MM cells25. Indatuximab ravtansine showed encouraging anti-MM activity with a reasonable safety profile in a recent Phase Ib/IIa open label, multi-dose escalation, clinical trial in RRMM26. In a preclinical study, CD138-based chimeric antigen receptor T cells (CAR-T) also demonstrated significant killing of MM cells, without off tumor cytotoxicity against normal epithelial or endothelial cells27. An anti-CD138 mAb-based therapy with potent immune-mediated cytotoxicity could represent an effective and safer modality compared to an ADC or CAR-T. Both ADC and CAR-T approaches have potential liabilities or limitations, e.g., dose-limiting toxicities in the case of ADCs or a less durable clinical response, cytokine release syndrome, prohibitive cost of manufacture, and limited point of patient access in the case of CAR-T.
We here developed a novel anti-CD138 mAb VIS832 and characterized its mode of actions in multiple preclinical models of MM. In concert with its effective immune-mediated killing of MM cells as a single agent, in vitro and in vivo evaluations of VIS832 combined with len or btz demonstrated augmented efficiency and tolerability, providing the rationale for its clinical evaluation in MM.
Materials and methods
CD138 antibodies
VIS832 was produced by transient vector transfection in Chinese hamster ovary cells, as described in Supplementary Methods. The secreted mAb was purified from cell culture media using protein A affinity capture on Fast Protein Liquid chromatography (FPLC), in accordance with established protocols.
Antibody-dependent cellular cytotoxicity (ADCC) assay
ADCC activity was mainly measured based on the calcein-AM release from calcein-AM labeled target MM cells co-incubated with human NK or PBMC effector cells isolated from multiple healthy donors or MM patients, in the presence of test Abs. Unless otherwise noted, target MM cells and NK effector cells were co-cultured at an effector: target (E:T) ratio of 10:1. ADCC data following antibody titration were plotted using a nonlinear regression analysis and a 4-parameter curve fit (GraphPad), from which EC50 values were calculated.
Bioluminescence (BLI)-based assays were also used when target MM cell transfectants expressing a luciferase gene were used28. When determining VIS832-induced ADCC against autologous patient MM cells in BMMCs from patient BM samples, flow cytometry-based analysis gated on viable BCMA+ fraction was used.
Antibody-dependent cellular phagocytosis (ADCP) assay
Indicated target MM cell lines (nāā„ā5) sensitive or resistant to dexamethasone (dex), IMiDs, or dara were labeled with a fluorescence cell membrane dye Cell Traceā¢ Far Red, washed, and incubated for 4āh with macrophages labeled green with CFSE in the presence of VIS832 or antibody isotype control in triplicate at indicated E:T ratios (1:1, 2:1, or 4:1). Cells were fixed with 1% paraformaldehyde followed by flow cytometry to detect double-positive (DP) fluorescence, an indication of phagocytic activity29.
Murine model of disseminated human MM disease
The in vivo efficacy of VIS832 and btz, alone or in combination, were evaluated using a murine model of the dissemination of MM1S-luc cells intravenously (i.v.) injected into CB-17 SCID mice. After 14 days, whole body tumor burden was monitored by BLI. Mice (nā=ā9 per group) were randomized and treatments started. Vehicle control (PBS) was dosed once daily by intraperitoneal (i.p.) injection (0.2āml/20āg per mouse); VIS832 (4āmg/kg) and btz (1āmg/kg) were dosed twice weekly by i.p. injection for 52 days. Treatment in all groups was discontinued at Day 53; surviving animals were monitored for an additional 3 weeks till Day 73.
See Supplementary āMaterials and Methodsā for additional details.
Results
Robust binding of VIS832 to CD138 on MM cell lines and patient MM cells
CD138 protein and mRNA levels were first assayed by flow cytometry analysis using an anti-CD138 DL-101 clone and qRT-PCR, respectively, in MM cell lines (nā=ā12) including paired sensitive and resistant to dex (MM1S/MM1R), IMiDs (both len and pom) (MM1S/MM1S(R), H929/H929(R)), and btz (ANBL6/ANBL6-BR)28,30 (Supplementary Fig. S1A). All MM cell lines highly expressed CD138, as shown by geometric mean fluorescence intensity (MFI) values, with some variability in relative expression levels. MM cell lines (nā=ā29) expressed highest CD138 levels, compared with 10 other hematological cancer cell line cohorts (Supplementary Fig. S1B). Soluble CD138 generally correlated with protein and transcript levels in most of the corresponding MM cell lines (Supplementary Fig. S1C) and was elevated in patient serum samples vs. healthy donors (Pā<ā0.001) (Supplementary Fig. S1D).
VIS832 is a humanized IgG1Īŗ mAb targeting human CD138 and has been optimized for its binding avidity to cell membrane CD138. The epitope of VIS832 includes a membrane proximal region of CD138 predicted to confer productive immune synapse formation for improved Fc effector-dependent, immune cell-mediated cytotoxicity. The relative binding affinity of VIS832 to MM cells was compared with anti-CD138 antibody BB4, whose VH and VL variable regions comprise the paratope for indatuximab ravtansine25,26. VIS832 showed robust and dose-dependent target engagement, with potent binding avidity (sub-to low-nanomolar) across MM cell lines (nā=ā8), as indicated by MFI values (Fig. 1a). Significantly, binding of VIS832 was more intense (Pā<ā0.005) than BB4 in all MM cell lines, with multi-fold increases in apparent binding affinity (Supplemental Table S1). Importantly, VIS832 showed dose- and CD138 target-dependent binding of PCs derived from BM of patients (4 RR and 1 SMM) (Fig. 1b). Thus, VIS832 is a potential therapeutic candidate targeting CD138 for further investigation in human MM.
VIS832 directs target-specific ADCC against MM cell lines with acquired resistance to current therapies and in the presence of MM growth promoting BM cells
Antibody-dependent cellular cytotoxicity (ADCC) is an effective and therapeutically validated immune-based mechanism for targeted MM cell killing29,31,32,33,34,35,36. ADCC of VIS832 was first determined using a reporter bioassay comprised of an engineered Jurkat cell line overexpressing the human FcĪ³RIIIa receptor as effector cell surrogate co-cultured with target U266 MM cell line. EC50 value for VIS832 was ~99.31āng/ml (0.66ānM), whereas the BB4 possessing an isotype matched human IgG1 induced only minimal ADCC (Fig. 1c). Afucosylation of the Fc N glycan on VIS832 further optimized its efficiency and potency, with decreased EC50 and >7-fold increased maximal U266 MM cell lysis (28.67āng/ml (0.2ānM), Supplemental Fig. S2).
Using calcein-AM release assay, VIS832 ADCC activity was next quantified in the co-cultures of calcein-AM-pre-labeled MM cell lines with NK cells from multiple healthy donors (nāā„ā3). VIS832, dose-dependently, induced ADCC against MM cell lines (nā=ā12) (Supplementary Fig. S3A). EC50 values of VIS832 ranged from 2.22āĀ±ā0.37 to 15.3āĀ±ā2.71āng/ml, and % maximal lysis ranged from 37.06āĀ±ā1.45% to 97.3āĀ±ā3.34% across tested MM cell lines (Fig. 2a and Supplementary Table S2). VIS832-induced ADCC against MM cells generally correlated with CD138 surface expression levels (Supplementary Fig. S3B). VIS832-induced lower ADCC activity against target JJN3 (Fig. 2a, b) and ANBL6 (Fig. 2a, c) MM cells, presumably due to relatively lower CD138 expression (e.g., relative to levels in H929 or MM1S). VIS832-induced ADCC against MM cell lines was also consistent with ADCC activity induced by the parental mAb 2810, the non-humanized predecessor to VIS832 (Supplementary Fig. S3C). These comparable data (Supplementary Table S2, EC50 values ranging from 2.39 to 28.16āng/ml across 10 MM cell lines) confirmed the successful antibody humanization of VIS832 with full retention of biological activity.
The dependency of CD138 expression on VIS832-induced NK cell-mediated MM cell lysis was validated using two CRISPR/CAS9-generated CD138 (SDC1) gene knockout (KO) H929 and JJN3 MM cell lines (Supplementary Fig. S3D). VIS832 did not induce ADCC against CD138 KO transfectants vs. the parental (target control, NT) cells with high (in H929) and low (in JJN3) CD138 levels (Fig. 2b).
VIS832 induced equivalent ADCC against paired MM cell lines sensitive and resistant to dex (MM1S/MM1R), len/pom-(H929/H929(R)), and btz (ANBL6/ANBL6-BR) (Fig. 2a, c). In the presence of BM stromal cells (BMSCs) or osteoclasts (OCs)37,38,39,40, two key MM-supporting accessory cells in the BM milieu, VIS832-induced ADCC against MM cells was minimally affected (Fig. 2d). These data indicated that VIS832 could generate potent cytotoxicity in MM cells resistant to current therapies and in the tumorigenic (and generally immunosuppressive) BM microenvironment.
VIS832 effectively targets autologous patient MM cells
VIS832-dependent ADCC against autologous patient CD138ā+ācells was next evaluated using BMMCs freshly isolated from patient BM aspirates (nā=ā7, including 6 RRMM and 1 SMM (MM12)). BMMCs that included CD138ā+āMM cells, immune cells, and other BM accessory cells, were directly incubated with various dilutions of VIS832 for 1 day. The fraction of viable patient MM cells was independently measured by quantitative flow cytometry analysis after staining with an mAb against BCMA, another PC marker41,42. VIS832-induced autologous cytolysis of patient MM cells was determined by the elimination of the viable BCMA+ cell population relative to control (Supplementary Fig. S4). VIS832 depleted patient MM cells in a dose-dependent manner (Fig. 2e, left), inducing >60% maximal lysis of autologous patient MM cells, with >90% killing in 4 out of 7 MM patient samples. These results also replicated ADCC data in another RRMM patient cohort (nā=ā6, MM13-18) treated with the parental 2810 mAb, including 90% killing in 3 of 6 MM patient samples (Fig. 2e, right). EC50 values ranged from 8.58 to 86.04 and 17.28ā179.3āng/ml for VIS832 and 2810 mAb, respectively.
Paired CD138-positive and CD138-negative patient cell populations were next separated and pre-labeled with calcein-AM, followed by co-culture with autologous PBMCs (nā=ā3) in the presence of VIS832 (0ā1āĀµg/ml). Specific ADCC activity was both VIS832-dependent and required CD138ā+ātarget patient MM cells (Fig. 2f). The correlation of MM cell binding and ADCC using VIS832 and 2810 mAb, therefore, corroborated effective CD138 target engagement, leading to productive and specific autologous patient MM cell killing.
VIS832 showed increased ADCC potency than dara and directs significant target-specific killing of dara-resistant MM cells without depleting NK cells
We next evaluated relative potencies of VIS832 vs. daratumumab (dara), to induce effector cell-dependent killing of target MM cell lines using luminescence-based (Fig. 3a) and flow cytometry analysis (Fig. 3b). Dara targeting CD38 has recently been approved to treat newly diagnosed MM43. VIS832, more potently than dara, increased maximal lysis by ~3-fold of all target MM cell lines, regardless of resistance to both IMiDs. Higher MM1S cell lysis induced by VIS832 vs. dara was also confirmed in BCMA-based flow cytometry analysis (Pā<ā0.05). These results confirmed significantly higher CD138 vs. CD38 levels in all MM cell lines (Pā<ā0.0001, Supplementary Fig. S5A). Importantly, patient MM cells also expressed significantly higher CD138 vs. CD38 (Pā<ā0.0001), and CD138 levels were further increased with progression of disease (Supplementary Fig. S5A, B).
We next asked whether VIS832 remained active against MM cells resistant to dara. CD38 knock-out (CD38 KO) through CRISPR/CAS9 gene editing was done in H929 cells to derive 2 CD38 KO transfectants (Supplementary Fig. S5C). VIS832 induced equivalent ADCC to lyse CD38 KO transfectants and the parental control H929 (H929 NT) cells (Fig. 3c). CD138 levels were unchanged in CD38 KO and parental control H929 cells. The dose response curves for three cell lines overlapped, with similar % maximal lysis and EC50 values of VIS832. Compared to dara, VIS832 induced significantly higher ADCC, with increased maximal lysis (~2.7-fold higher) of the parental H929 target cells. In contrast, dara failed to induce ADCC against CD38 KO H929 transfectants. We also developed dara-resistant RPMI8226 (RPMI8226-DR) cells via extended exposure of dara in ex vivo NK-MM co-cultures. Unlike RPMI8226 cells, dara did not induce ADCC against RPMI8226-DR cells, confirming resistance to dara (Fig. 3d). VIS832 still induced lysis of RPMI8226-DR to a similar extent as its parental RPMI8226 cells. Again, VIS832, more effectively than dara, induced greater % maximal lysis of the parental RPMI8226 cells.
The effect of VIS832 on MM-specific NK cell activation was next assayed by quantitative flow cytometry analysis for % CD107a surface expression on CD56ā+āCD3- cells in the NK-MM co-culture. VIS832 induced CD107a degranulation in NK cells in a MM cell- and concentration-dependent manners (Fig. 3e).
NK cells express CD38 at the highest level among other normal hematological lineage cells. In fact, dara depletes patient NK cells within the first week after treatment, affecting its efficacy to target MM cells and thereby limiting durability of responses36,44. Using annexin V staining followed by flow cytometry analysis to measure apoptotic cell fraction, dara, but not VIS832, induced NK cell death in a concentration-dependent manner after 1-day treatment (Fig. 3f). Thus, unlike dara, VIS832 even selectively induced MM cell lysis via NK activation, without depleting NK cells.
Enhancement of targeted cellular killing activity of VIS832 in combination with lenalidomide or bortezomib
IMiDs (len and pom), which upregulate ADCC ability of therapeutic mAbs29,32,34, are routinely used in combination with dex in mAb-based immunotherapies in MM. Using calcein-AM release assays in MM-NK cell co-cultures at lower E:T ratio of 4:1, we next tested effects of len on VIS832-induced cytotoxicity against MM cells. When VIS832 and len were added concomitantly, synergistic MM cell lysis was seen, with combination index (CI) values of <1 at all concentrations of both drugs (Fig. 4a and Supplementary Fig. S6A). Pretreatment with len alone for 3 days did not induce significant killing of MM1S and MM1R target cell lines (<10%) (Fig. 4b). Also, VIS832 significantly induced higher ADCC against MM1S and MM1R target cells pretreated with len when compared to control medium groups (Pā<ā0.05), with CI values <1 (Supplementary Fig. S6B).
Furthermore, VIS832-induced ADCC against target MM cell lines H929 and RPMI8226 was also synergistically enhanced when VIS832 combined with btz, at even lower E:T ratio of 1:1, with CI values of <1 (Fig. 4c, d and Supplementary Fig. S6C, D).
VIS832 induced antibody-dependent cellular phagocytosis (ADCP) against MM cells sensitive and resistant to dex, IMiDs, or dara
ADCP activity was next measured by dual colored flow cytometry analysis using in vitro culture-differentiated macrophages co-incubated with target MM1R cells resistant to dex. Percentage of phagocytosis as the double-positive (DP) fraction was quantitated in the presence of VIS832, isotype control Ab, or no Ab control, at various macrophage effector to MM cell ratios. Dara served as a positive control for its reported ADCP activity45. Phagocytosis was dependent on both VIS832 (e.g., in comparison to the isotype control antibody) and the E:T ratio (Pā<ā0.001, Fig. 5a). The ADCP activity of VIS832 was significantly higher than that observed for dara (Pā<ā0.05, Fig. 5a, b). Furthermore, VIS832-induced ADCP was comparable in MM cell lines sensitive or resistant to IMiDs and dara (Fig. 5b). While dara failed to induce ADCP against RPMI822-DR cells, VIS832 still induced significant ADCP (Pā<ā0.0001).
VIS832 efficacy in a murine model of disseminated human MM
In vivo VIS832 efficacy was assessed using a murine model xenografted with the dissemination of MM1S-luc cells by i.v. injection into CB-17 SCID mice, which preserve aspects of innate immunity relevant to antibody mechanisms of action29,31,32, including NK cell- and macrophage-mediated cytotoxicity of antibody-targeted CD138-expressing MM cells. Dosing intervals and route of administration (nā=ā9 mice per group) were as described in methods and in Fig. 6a. Whole BLI of MM1S-luc cells was used to non-invasively quantify site-specific disease burden (Supplementary Fig. S7).
In the vehicle control (VC, PBS) group, the median time to evaluation size was ~28 days, and the median tumor burden doubling time was 2 days (range of 1.5ā2.2 days), consistent with tumor implantation in all animals and an aggressive progression of tumor growth. The median survival of animals in the VC group was 30 days, and all animals were deceased by day 51 (Table 1 and Supplementary Tables S3 and 4). In contrast, VIS832 monotherapy at 4āmg/kg effectively reduced tumor burden with a prolonged time to evaluation (Supplementary Table S4, median survival of >60 days), and reduction of disseminated tumor growth (Fig. 6b and Supplementary Fig. S7). Five of 9 animals (56%) remained on study for its duration (day 73). Significant survival benefit of VIS832 was noted at day 53 (Pā<ā0.0001, Fig. 6c), 3 weeks following treatment discontinuation. VIS832 treatment also led to disease regression in a subset of mice evaluated up to day 53 (the last day of dosing).
In the combination group, a sub-optimal dose of btz was chosen (1āmg/kg) that achieved a tumor growth delay of ~10 days and a 40% increase in lifespan, but no animals exhibited either partial or complete regression or survived (median survival of 42 days) to the end of study at Day 73 (Fig. 6 and Supplementary Table S4). VIS832 alone significantly extended host survival when compared with btz (Pā=ā0.02). Combined VIS832 and btz treatments significantly enhanced efficacy, evidenced by complete tumor regression and 100% survival to end of study (Fig. 6c). Clear survival advantages were confirmed (Pā<ā0.0001 for combination vs. VC; Pā<ā0.02 for combination vs. VIS832; Pā<ā0.0001 for combination vs. btz). This efficacy was sustained even after discontinuation of treatment on Day 53, 3 weeks prior to study termination. The apparent lack of any discernible tumor burden suggested an achievement of minimal residual disease in animals receiving combination therapy. Loss of body weight during the first week of treatment and mean body weight change was minimal (<5%). In fact, animals treated with 4āmg/kg VIS832 experienced an upward trend in mean body weight. In contrast, treatment-related toxicity was observed in the two groups initially receiving btz at the 2āmg/kg dose level, but reduction in dose from 2āmg/kg to 1āmg/kg led to recovery of body weight, particularly in mice receiving 1āmg/kg of btz and 4āmg/kg VIS832 combination.
Thus, VIS832 induced significant in vivo anti-MM activity as monotherapy, and further completely eradicated MM in mice treated in combination with btz.
Discussion
Given its enhanced and prevalent presentation on the MM cell surface, CD138 is a compelling target for immunotherapy in MM. Many of the previously characterized anti-CD138 mAbs, such as BB4 in indatuximab ravtansine, target the integrin binding domain (IBD), an immunodominant region of CD138, which is distally located from the cell membrane. VIS832 evaluation has been sufficiently characterized with respect to its physicochemical and biophysical attributes, as measured by several different drug ādevelopabilityā assays and metrics indicating favorable pharmaceutical properties. It engages a differentiated epitope on CD138 comprising two, non-contiguous regions that are required for optimal target binding. Importantly, when measured in the same assay, we showed stronger and more intense binding of VIS832 vs. BB4 to all MM cell lines, including those with relatively lower CD138 density. In parallel, further structural modeling of ADCC for well characterized antibodies such as rituximab with potent Fc-mediated ADCC indicates the critical importance of epitope location and topological proximity to the cell surface as a key determinant of immune synapse formation46. The epitope recognized by VIS832 includes a membrane proximal region of CD138 whose targeted binding is predicted to confer productive immune synapse formation for improved Fc effector dependent, immune cell-mediated cytotoxicity. As such, indatuximab ravtansine, which targets the IBD of CD138, is predicted to exhibit poor immune cell-based killing25 when compared with VIS832. Indeed, VIS832 induces superior MM cell lysis than the BB4 possessing an isotype matched human IgG1.
VIS832-dependent NK cell-mediated cytotoxicity, while target dependent, did not precisely correlate with CD138 surface expression levels on target cells. This suggests a sufficiency of CD138 target abundance (threshold) to drive a potent antibody-mediated biological response. Other aspects include VIS832 target epitope engagement, target binding avidity, and other yet identified mechanisms of action. Significantly, our data indicate that the differentiated epitope of VIS832 in comparison with BB4 within indatuximab ravtansine confers a more productive target binding and augmented Fc effector function, leading to improved immune synapse formation, and ultimately to its more potent MM targeting and superior cellular cytotoxicity activity, including ADCC and ADCP.
Besides ADCC that presumptively represents a primary mechanism for the biological potency of VIS832, VIS832 delivered additional Fc-mediated ADCP to eliminate MM cells. ADCP activity of therapeutic mAbs including dara and GSK2857916 (belantamab mafodotin) is an important mechanism for their in vivo potency29,35,41. Significantly, VIS832 exhibited increased ADCP activity than dara in multiple MM cell lines, regardless of resistance to dex and IMiDs. VIS832 induced comparable ADCP to deplete RPMI8226-DR cells resistant to dara, indicating ADCP as a crucial mechanism of action of VIS832 to overcome dara resistance. This supplementary cytotoxic function of VIS832 confirms its multi-faceted immune-mediated anti-MM activity, which could aid in overcoming multi-drug resistance and prolonging response.
As in the case for dara, elotuzumab, isatuximab, and belantamab mafodotin29,34,47,48,49, the activating effect of len on immune effector cells also augments VIS832-induced cytotoxicity against MM cells. Such enhanced efficacy of combination vs. monotherapy likewise would be anticipated with other IMiDs including pom. Higher maximal killing of MM cells of VIS832 than dara also correlated with higher CD138 than CD38 target expression. VIS832 still potently induced ADCC against MM cells resistant to dara, either due to the loss of CD38, or acquired drug resistance through long-term culture selection with dara in ex vivo NK-MM co-cultures. Moreover, dara, but not VIS832, induced apoptosis in NK cells. Thus, VIS832 would not deplete NK cells, thereby avoiding any negative impact on its efficacy and therapeutic window.
VIS832, like its predecessor mAb 2810, induced robust immune cell-mediated cellular killing of patients MM cells resistant to btz, IMiDs, and/or dara. Its selective cytotoxicity against autologous patient MM cells was confirmed using whole BMMCs, as well as purified CD138ā+ācells freshly harvested from patients. Since various BM accessory cells confer immunosuppression, these data suggest that VIS832 would be active in the patient BM milieu. Its selective ADCC against autologous patient MM cells, but not CD138-negative BM cells, further supporting a favorable therapeutic index.
The in vivo efficacy of VIS832 was convincingly demonstrated in an aggressive disseminated MM1S xenograft model of human MM in CB-17 SCID mice, both as monotherapy and in combination with btz. When used alone, VIS832 reduced median tumor burden and improved overall survival. This efficacy was sustained after discontinuation of treatment 3 weeks prior to study termination. An evaluation of VIS832 PK/PD relationships in a prior dose range finding study in the same in vivo model indicated sufficient exposure of VIS832 at this dose level (4āmg/kg) to achieve a biological response (data not shown). Even lower dose levels, while not evaluated, are predicted to be sufficient to achieve such a response. Importantly, administration of VIS832 was well tolerated, with no overt treatment-related morbidities or toxicities, especially seen in btz-treated group.
Combined treatment of tumor-bearing mice with both VIS832 and dose-adjusted btz resulted in complete tumor regression and 100% survival of all animals to the end of study at day 73. Complete tumor elimination in all mice was sustained even after discontinuation of treatment on Day 53, 3 weeks prior to study termination. The apparent lack of any discernible tumor burden suggests an achievement of minimal residual disease in animals receiving the two therapies at sub-optimal doses in combination. Moreover, the superior efficacy of combined VIS832 and btz when compared to either agent alone suggests synergistic in vivo activity, consistent with synergistic in vitro cytotoxicity of this combination (CIā<ā1). Recently, CD138 downregulation sensitizes MM cells to btz treatment in another animal model50. The augmentation of activity of low-dose btz by VIS832 shown here suggests enhanced efficacy and tolerability at lower doses in the clinic.
Taken together, the significant in vivo efficacy of VIS832 in the MM1S xenograft murine model, coupled with its mechanisms of action and in vitro MM cytotoxicity, both confirm CD138 as a promising MM target and provide the basis for clinical development of VIS832 as a potentially effective mAb-based immunotherapy. Given the current therapeutic landscape and clinical approaches to MM treatment, the use of immune targeted therapies including VIS832 will likely be best suited to augment standard-of-care through an appropriate use of drug combinations, and/or as additional lines of therapies in MM. Such an approach will be of particular therapeutic value in the treatment of patients with relapsed disease and/or refractory to prior treatment (e.g., dara). Indeed, our current data indicate that VIS832 can overcome resistance to dex, btz, and IMiDs. Once its efficacy is established in RRMM, its favorable therapeutic index should allow for moving rapidly to earlier stages of disease, newly diagnosed MM and even SMM.
References
Kumar, S. K. et al. Multiple myeloma. Nat Rev. Dis. Primers 3, 17046 (2017).
Rajkumar, S. V. Multiple myeloma: 2018 update on diagnosis, riskāstratification, and management. Am. J. Hematol. 93, 981ā1114 (2018).
Chim, C. S. et al. Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond. Leukemia 32, 252ā262 (2018).
Pawlyn, C. & Morgan, G. J. Evolutionary biology of high-risk multiple myeloma. Nat. Rev. Cancer 17, 543ā556 (2017).
Hassan, H. et al. Syndecan-1 modulates beta-integrin-dependent and interleukin-6-dependent functions in breast cancer cell adhesion, migration, and resistance to irradiation. FEBS J. 280, 2216ā2227 (2013).
Barbouri, D. et al. Syndecans as modulators and potential pharmacological targets in cancer progression. Front. Oncol. 4, 4 (2014).
Beauvais, D. M. et al. Syndecan-1 (CD138) suppresses apoptosis in multiple myeloma by activating IGF1 receptor: prevention by synstatinIGF1R inhibits tumor growth. Cancer Res. 76, 4981ā4993 (2016).
McCarron, M. J., Park, P. W. & Fooksman, D. R. CD138 mediates selection of mature plasma cells by regulating their survival. Blood 129, 2749ā2759 (2017).
Akl, M. R. et al. Molecular and clinical profiles of syndecan-1 in solid and hematological cancer for prognosis and precision medicine. Oncotarget 6, 28693ā28715 (2015).
Khotskaya, Y. B. et al. Syndecan-1 is required for robust growth, vascularization, and metastasis of myeloma tumors in vivo. J. Biol. Chem. 284, 26085ā26095 (2009).
Sanderson, R. D. & Yang, Y. Syndecan-1: a dynamic regulator of the myeloma microenvironment. Clin. Exp. Metastasis 25, 149ā159 (2008).
Yang, Y. et al. The syndecan-1 heparan sulfate proteoglycan is a viable target for myeloma therapy. Blood 110, 2041ā2048 (2007).
Seidel, C. et al. High levels of soluble syndecan-1 in myeloma-derived bone marrow: modulation of hepatocyte growth factor activity. Blood 96, 3139ā3146 (2000).
Aref, S., Goda, T. & El-Sherbiny, M. Syndecan-1 in multiple myeloma: relationship to conventional prognostic factors. Hematology 8, 221ā228 (2003).
Andersen, N. F. et al. Syndecan-1 and angiogenic cytokines in multiple myeloma: correlation with bone marrow angiogenesis and survival. Br. J. Haematol. 128, 210ā217 (2005).
Seidel, C. et al. Serum syndecan-1: a new independent prognostic marker in multiple myeloma. Blood 95, 388ā392 (2000).
Rajkumar, S. V., Landgren, O. & Mateos, M. V. Smoldering multiple myeloma. Blood 125, 3069ā3075 (2015).
Lakshman, A. et al. Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria. Blood Cancer J. 8, 59 (2018).
Bolli, N. et al. Genomic patterns of progression in smoldering multiple myeloma. Nat. Commun. 9, 3363 (2018).
Detweiler-Short, K. et al. Long-term results of single-agent thalidomide as initial therapy for asymptomatic (smoldering or indolent) myeloma. Am. J. Hematol. 85, 737ā740 (2010).
Sundararajan, S., Kumar, A., Korde, N. & Agarwal, A. Smoldering multiple myeloma: emerging concepts and therapeutics. Curr. Hematol. Malig. Rep. 11, 102ā110 (2016).
Bustoros, M. et al. Genomic profiling of smoldering multiple myeloma identifies patients at a high risk of disease progression. J. Clin. Oncol. 0, JCO.20.00437 (2020).
Landgren, C. O. et al. Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS). Leukemia 34, 1840ā1852 (2020).
Lonial, S. et al. Randomized trial of lenalidomide versus observation in smoldering multiple myeloma. J. Clin. Oncol. 38, 1126ā1137 (2020).
Ikeda, H. et al. The monoclonal antibody nBT062 conjugated to cytotoxic Maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivo. Clin. Cancer Res. 15, 4028ā4037 (2009).
Jagannath, S. et al. Indatuximab ravtansine (BT062) monotherapy in patients with relapsed and/or refractory multiple myeloma. Clin. Lymphoma Myeloma Leuk. 19, 372ā380 (2019).
Sun, C. et al. Safety and efficacy of targeting CD138 with a chimeric antigen receptor for the treatment of multiple myeloma. Oncotarget 10, 2369ā2383 (2019).
Xing, L. et al. A novel BCMA PBD-ADC with ATM/ATR/WEE1 inhibitors or bortezomib induce synergistic lethality in multiple myeloma. Leukemia 34, 2150ā2162 (2020).
Tai, Y. T. et al. Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma. Blood 123, 3128ā3138 (2014).
Lin, L. et al. Preclinical evaluation of CD8+ anti-BCMA mRNA CAR T cells for treatment of multiple myeloma. Leukemia https://doi.org/10.1038/s41375-020-0951-5 (2020).
Tai, Y. T. et al. Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu. Blood 112, 1329ā1337 (2008).
Tai, Y. T. et al. Potent in vitro and in vivo activity of an Fc-engineered humanized anti-HM1.24 antibody against multiple myeloma via augmented effector function. Blood 119, 2074ā2082 (2012).
de Weers, M. et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J. Immunol. 186, 1840ā1848 (2011).
Jiang, H. et al. SAR650984 directly induces multiple myeloma cell death via lysosomal-associated and apoptotic pathways, which is further enhanced by pomalidomide. Leukemia 30, 399ā408 (2016).
Nijhof, I. S. et al. Preclinical evidence for the therapeutic potential of CD38-targeted immuno-chemotherapy in multiple myeloma patients refractory to lenalidomide and bortezomib. Clin. Cancer Res. 21, 2802ā2810 (2015).
Krejcik, J. et al. Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma. Blood 128, 384ā394 (2016).
An, G. et al. Osteoclasts promote immune suppressive microenvironment in multiple myeloma: therapeutic implication. Blood 128, 1590ā1603 (2016).
Tai, Y. T., Cho, S. F. & Anderson, K. C. Osteoclast immunosuppressive effects in multiple myeloma: role of programmed cell death ligand 1. Front. Immunol. 9, 1822 (2018).
Tai, Y. T. et al. Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma. Blood 120, 1877ā1887 (2012).
Tai, Y. T. et al. CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications. Leukemia 28, 155ā165 (2014).
Cho, S. F. et al. BCMA-targeting therapy: driving a new era of immunotherapy in multiple myeloma. Cancers (Basel) 12, 1473. https://doi.org/10.3390/cancers12061473 (2020).
Tai, Y. T. & Anderson, K. C. B cell maturation antigen (BCMA)-based immunotherapy for multiple myeloma. Expert Opin. Biol. Ther. 19, 1143ā1156 (2019).
Mateos, M. V. et al. Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial. Lancet 395, 132ā141 (2020).
Wang, Y. et al. Fratricide of NK cells in daratumumab therapy for multiple myeloma overcome by ex vivo-expanded autologous NK cells. Clin. Cancer Res. 24, 4006ā4017 (2018).
Overdijk, M. B. et al. Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma. MAbs 7, 311ā321 (2015).
Cleary, K. L. S. et al. Antibody distance from the cell membrane regulates antibody effector mechanisms. J. Immunol. 198, 3999ā4011 (2017).
Feng, X. et al. Targeting CD38 suppresses induction and function of T regulatory cells to mitigate immunosuppression in multiple myeloma. Clin. Cancer Res. 23, 4290ā4300 (2017).
van der Veer, M. S. et al. Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab. Haematologica 96, 284ā290 (2011).
Zhang, L. et al. Regulatory B cell-myeloma cell interaction confers immunosuppression and promotes their survival in the bone marrow milieu. Blood Cancer J. 7, e547 (2017).
Akhmetzyanova, I. et al. Dynamic CD138 surface expression regulates switch between myeloma growth and dissemination. Leukemia 34, 245ā256 (2020).
Acknowledgements
We acknowledge the technical assistance from the flow cytometry facility at Dana-Farber Cancer Institute (DFCI). We especially thank Drs. Jiye Liu and Eugenio Morelli at DFCI, Dr. Ronald Taylor at University of Virginia for helpful technical assistance and discussion for in vitro experiments. We thank Hamid Tissire and Ketan Deotale (Visterra, Inc.) for valuable technical assistance in the biochemical characterization of anti-CD138 antibodies. We thank all other lab members as well as the clinical research coordinators at the Jerome Lipper Multiple Myeloma Center and the LeBow Institute for Myeloma Therapeutics of the DFCI for all support and help in providing primary tumor specimens for this study. This work was supported in part by grants from the National Institutes of Health Specialized Programs of Research Excellence (SPORE) P50 CA100707, P01CA155258, RO1 CA 207237, R01 CA050947. This work was supported in part by Dr. Miriam and Sheldon G. Adelson Medical Research Foundation and the Riney Family Multiple Myeloma Initiative. Dr. Kenneth C. Anderson is an American Cancer Society Clinical Research Professor.
Author information
Authors and Affiliations
Contributions
Conception and design: J.R.M., K.C.A., Y.-T.T. Development of methodology: T.Y., B.C., L.L., B.R., L.X., Y.T.T., Z.S., J.R.M. Acquisition of data: T.Y., L.L., B.C., B.R., L.X., S.-F.C., Y.L., K.W., P.A.H., H.C., W.Y., Y.X., G.A., L.Q., A.W., K.V., H.A. Analysis and interpretation of data (statistical analysis, biostatistics analysis): T.Y., B.C., L.L., L.X., B.R., S.-F.C., Y.L., K.W., G.B., J.R.M., Y.-T.T. Reagents provided: Z.S., J.R.M. Animal work plan and data requisition and analysis: Z.S., J.R.M. Provided and managed patient samples: N.M., K.C.A. Writing, review, and/or revision of the manuscript: T.Y., J.R.M., K.C.A., Y.-T.T. Study supervision: K.C.A., Y.-T.T.
Corresponding authors
Ethics declarations
Conflict of interest
B.C., B.R., A.W., K.V., H.A, G.B., Z.S., and J.R.M. are employees of Visterra Inc. N.M. serves on advisory boards to Millennium-Takeda, Celgene, and Novartis. K.C.A. serves on advisory boards Celgene, Millennium-Takeda, Bristol-Myers Squibb, Gilead Sciences, Janssen, and Sanofi-Aventis and is a Scientific founder of OncoPep and C4 Therapeutics. All other authors declare no potential conflicts of interest.
Additional information
Publisherās note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary information
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the articleās Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the articleās Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Yu, T., Chaganty, B., Lin, L. et al. VIS832, a novel CD138-targeting monoclonal antibody, potently induces killing of human multiple myeloma and further synergizes with IMiDs or bortezomib in vitro and in vivo. Blood Cancer J. 10, 110 (2020). https://doi.org/10.1038/s41408-020-00378-z
Received:
Revised:
Accepted:
Published:
DOI: https://doi.org/10.1038/s41408-020-00378-z
This article is cited by
-
MZ1, a BRD4 inhibitor, exerted its anti-cancer effects by suppressing SDC1 in glioblastoma
BMC Cancer (2024)
-
Dysregulation of IL-34 ligation to SDC-1 mitigates collagen-induced arthritis
Cellular & Molecular Immunology (2022)